Zacks Investment ResearchT3·11h ago
IBBQ Invesco Nasdaq Biotechnology ETF
ETF 36.85 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IBBQ
$36.85
—
Key stats
$36.85
- 52-Week Range
- $26.57 – $37.01
- YTD
- +29.86%
- IV Rank (30D)
- 17.15
- Straddle Price
- $2.67
- P/C Vol Ratio
- 0.30
- Open
- $36.23
- Day Range
- $35.79 – $37.01
- Volume
- 100,233
- Prev Close
- $35.83
About
Invesco Nasdaq Biotechnology ETF (IBBQ) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2021-06-11
- Has Options
- Yes
- Homepage
- https://www.invesco.com/us/etfs
Fund profile
holdings as of Nov 5, 2026issuer datathrough Aug 2026flows, SEC filings
- Expense ratio
- 0.19% prospectus, filed Dec 18, 2025
- Assets
- $121M shares × price, Nov 6, 2026
- Trailing yield
- 1.09% paid quarterly
- Average daily volume
- $2.2M 30 sessions
- Holdings
- 255 top 10 are 48.8%
- Listed
- Jun 11, 2021 Nasdaq
- Tracking difference
- -0.07 pts vs index, after fees, FY 2025
Cost96
Liquidity45
Scale40
Diversification54
Moves with. US large-cap stocks (16% of its variance, beta 0.59); Small caps over large (9% of its variance, beta 0.53); Long Treasuries (6% of its variance, beta 0.44). These factors explain 36% of its daily moves over the last year.
Stated objective. The Invesco Nasdaq Biotechnology ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Nasdaq Biotechnology Index (the Underlying Index). (from the fund's prospectus)
All 255 holdingsFlow historySimilar fundsOverlap toolAll Biotech & Health Innovation ETFs
Fund flows
through Aug 2026SEC filings- Aug 2026
- +$14M latest reported month
- Latest 3 months
- +$16M +16.9% of assets
- Latest 12 months
- +$36M +37.8% of assets
View as a table
| Month | Net flow |
|---|---|
| Aug 2026 | +$14M |
| Jul 2026 | +$3.6M |
| Jun 2026 | −$936K |
| May 2026 | $0 |
| Apr 2026 | −$7.6M |
| Mar 2026 | $0 |
| Feb 2026 | +$294K |
| Jan 2026 | +$7.6M |
| Dec 2025 | +$5.7M |
| Nov 2025 | +$11M |
| Oct 2025 | +$2.3M |
| Sep 2025 | +$953K |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 63 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| IBBiShares Biotechnology ETF | 81% | 0.44% | $11.1B | +34.9% | compare |
| BIBProShares Ultra NASDAQ Biotechnology | 60% | 0.95% | $102M | +67.7% | compare |
| BBHVanEck Biotech ETF | 55% | 0.35% | $524M | +39.4% | compare |
| XBIState Street SPDR S&P Biotech ETF | 43% | 0.35% | $10.0B | +39.4% | compare |
| PBEInvesco Biotechnology & Genome ETF | 41% | 0.59% | $428M | +29.0% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Nov 5, 2026issuer data- Holdings vs fair value
- +7.8% 34% under, 29% over · 100% covered
- Price / earnings
- — 53% loss-making · 98% covered
- Price / book · sales
- 5.6 · 6.9 revenue growth +9.0%
- Above 200-day average
- 83% 73% above 50-day · by weight
- Short interest
- 8.1% of float, weighted · 5.3 days to cover
- Insider buying
- 4% of weight had net insider buying, 90 days; 56% net selling
- 13F holders
- +3.2% change in shares held by institutions, latest quarter
- Reporting earnings
- 10.9% of weight in 7 days; 10.9% in 14
Holdings reporting in the next 14 days · weighted implied move this week 1.60%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Nov 3, 2026 → Nov 4, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Exit | INDVIndivior Pharmaceuticals Inc | 0.28% | — | — |
| Increase | SUPNSupernus Inc | 0.16% | 0.42% | +257.8% |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 1.5%. Full holdings and history
Under the hood
fiscal year to Aug 31, 2025SEC census- Authorized participants
- 6 active of 41 with agreements; top 3 did 81%
- Created · redeemed
- $8.5M · $8.8M over the fiscal year
- Redemptions in kind
- 100% creations 100% in kind
- Creation unit
- 10,000 shares
- Securities lending
- 24.53% of assets on loan on average; earned 16.8 bp
- Return vs index
- -0.07 pts after fees; +0.11 before; daily s.d. 0.28
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-11-05
Holdings
256
AUM
$118.5M
Provider
Invesco
Inception
2021-06-11
Exchange
XNAS
Data As Of
2026-11-05
Expense Ratio
0.19%
Dividend Yield
1.09%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-21 | 2026-09-25 | $0.2304 | CD |
| 2026-06-22 | 2026-06-26 | $0.0342 | CD |
| 2026-03-23 | 2026-03-27 | $0.0361 | CD |
| 2025-12-22 | 2025-12-26 | $0.0906 | CD |
| 2025-09-22 | 2025-09-26 | $0.0958 | CD |
| 2025-06-23 | 2025-06-27 | $0.0287 | CD |
Asset Allocation
Top Holdings
top 50 of 256 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| GILD | Gilead Sciences Inc | 9.20% | Equity (US) | US |
| AMGN | Amgen Inc | 8.60% | Equity (US) | US |
| VRTX | Vertex Pharmaceuticals Inc | 8.00% | Equity (US) | US |
| MRNA | Moderna Inc | 6.34% | Equity (US) | US |
| REGN | Regeneron Pharmaceuticals Inc | 6.01% | Equity (US) | US |
| RVMD | Revolution Medicines Inc | 2.50% | Equity (US) | US |
| BIIB | Biogen Inc | 2.37% | Equity (US) | US |
| ILMN | Illumina Inc | 2.07% | Equity (US) | US |
| RPRX | Royalty Pharma PLC | 1.98% | Equity (Foreign) | GB |
| ROIV | Roivant Sciences Ltd | 1.74% | Equity (US) | US |
| ARGX | Argenx SE | 1.61% | Cash/Money Market | — |
| UTHR | United Therapeutics Corp | 1.60% | Equity (US) | US |
| INCY | Incyte Corp | 1.57% | Equity (US) | US |
| INSM | Insmed Inc | 1.56% | Equity (US) | US |
| VTRS | Viatris Inc | 1.43% | Equity (US) | US |
| ALNY | Alnylam Pharmaceuticals Inc | 1.38% | Equity (US) | US |
| GH | Guardant Health Inc | 1.35% | Equity (US) | US |
| MEDP | Medpace Holdings Inc | 1.17% | Equity (US) | US |
| EXEL | Exelixis Inc | 1.12% | Equity (US) | US |
| NBIX | Neurocrine Biosciences Inc | 1.07% | Equity (US) | US |
| ASND | Ascendis Pharma A/S | 1.02% | Equity (Foreign) | DK |
| BBIO | Bridgebio Pharma Inc | 0.98% | Equity (US) | US |
| JAZZ | Jazz Pharmaceuticals PLC | 0.97% | Equity (Foreign) | IE |
| HALO | Halozyme Therapeutics Inc | 0.92% | Equity (US) | US |
| ONC | BeOne Medicines Ltd | 0.91% | Cash/Money Market | — |
| TEM | Tempus AI Inc | 0.81% | Equity (US) | US |
| SMMT | Summit Therapeutics Inc | 0.74% | Equity (US) | US |
| BMRN | BioMarin Pharmaceutical Inc | 0.71% | Equity (US) | US |
| KYMR | Kymera Therapeutics Inc | 0.70% | Equity (US) | US |
| SNY | Sanofi SA | 0.67% | Cash/Money Market | FR |
| BNTX | BioNTech SE | 0.65% | Cash/Money Market | DE |
| MDGL | Madrigal Pharmaceuticals Inc | 0.61% | Equity (US) | US |
| PCVX | Vaxcyte Inc | 0.60% | Equity (US) | US |
| KRYS | Krystal Biotech Inc | 0.58% | Equity (US) | US |
| PTGX | Protagonist Therapeutics Inc | 0.58% | Equity (US) | US |
| SYRE | Spyre Therapeutics Inc | 0.56% | Equity (US) | US |
| IBRX | ImmunityBio Inc | 0.56% | Equity (US) | US |
| ARWR | Arrowhead Pharmaceuticals Inc | 0.53% | Equity (US) | US |
| TWST | Twist Bioscience Corp | 0.52% | Equity (US) | US |
| CYTK | Cytokinetics Inc | 0.51% | Equity (US) | US |
| ALKS | Alkermes PLC | 0.49% | Equity (Foreign) | IE |
| CAI | Caris Life Sciences Inc | 0.48% | Equity (US) | US |
| PRAX | Praxis Precision Medicines Inc | 0.48% | Equity (US) | US |
| RYTM | Rhythm Pharmaceuticals Inc | 0.48% | Equity (US) | US |
| TXG | 10X Genomics Inc | 0.46% | Equity (US) | US |
| AXSM | Axsome Therapeutics Inc | 0.45% | Equity (US) | US |
| AMRX | Amneal Pharmaceuticals Inc | 0.44% | Equity (US) | US |
| SUPN | Supernus Inc | 0.43% | Equity (US) | US |
| IONS | Ionis Pharmaceuticals Inc | 0.42% | Equity (US) | US |
| ORKA | Oruka Therapeutics Inc | 0.42% | Equity (US) | US |
Geographic Breakdown
Non-Equity Breakdown
Invesco Nasdaq Biotechnology ETF ·
NPORT-P period 2026-08-31
(filed 2026-10-30)
Net assets:
$96M
· 259 total positions
· equity 99.93%
· non-equity 19.96%
Non-equity holdings
— 3 positions,
19.96% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 19.96% | $19.2M | 3 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -12.54% | 4.30% | -1.62% | 4.62% | 2.53% | -0.54% |
| Feb | -- | -5.61% | -6.23% | -0.18% | 0.76% | 2.07% | -1.84% |
| Mar | -- | 4.91% | 0.73% | -1.99% | -4.07% | -3.03% | -0.69% |
| Apr | -- | -11.68% | 0.91% | -5.44% | 3.25% | -0.17% | -2.63% |
| May | -- | -2.30% | -3.68% | 3.44% | -3.00% | 3.47% | -0.41% |
| Jun | 1.27% | 2.12% | -0.15% | 1.74% | 1.93% | 11.65% | 3.09% |
| Jul | -1.38% | 1.93% | 1.92% | 6.59% | 4.80% | -1.62% | 2.04% |
| Aug | 4.29% | 0.99% | 0.83% | 1.79% | 4.46% | 10.92% | 3.88% |
| Sep | -5.78% | -4.30% | -4.89% | -1.08% | 2.11% | -1.82% | -2.63% |
| Oct | -0.16% | 7.46% | -5.22% | -1.99% | 7.07% | 5.08% | 2.04% |
| Nov | -5.15% | 5.06% | 3.14% | -1.27% | 10.08% | 3.51%* | 2.56% |
| Dec | 0.68% | -3.61% | 11.29% | -7.24% | 0.03% | -- | 0.23% |
| Total | -6.43% | -18.19% | 1.67% | -7.73% | 36.05% | 36.38% | 6.96% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $35.20
SMA 50: $35.02
SMA 200: $31.73
Current: $36.85
EMA 12: $35.78
EMA 26: $35.34
MACD: 0.4360 | Signal: 0.1260
BULLISH
ADX (14): 16.64
RANGE
+DI: 30.38
−DI: 18.03
Momentum Oscillators
RSI (14): 59.71
NEUTRAL
Stoch %K: 64.20
Stoch %D: 66.28
Williams %R: -5.87
Volume & Volatility
BB Upper: $37.12
BB Lower: $33.28
NEUTRAL
OBV: 1,104,112
Vol SMA 20: 64,559
Vol ROC: 31.45%
ATR: $0.91
True Range: $1.22
HV 20: 33.5%
HV 30: 30.8%
HV 60: 29.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers:
- Bullish MACD signal
- Neutral RSI reading
- Low volatility regime
Primary Risks:
- Lack of clear technical trend direction
- Limited recent news sentiment impact
- High IV rank indicating low volatility
Investment Thesis: IBBQ presents a mixed bag, with both bullish and bearish signals present. The stock's low volatility regime and neutral RSI reading indicate a stable environment, while the MACD signal suggests potential for further gains.
Recent News Sentiment Impact: The recent news headlines have been generally neutral, with no significant impact on the stock price. However, the positive sentiment of headlines 4 and 5 may contribute to the stock's slight upward momentum.
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL (no clear trend direction)
- Medium-term: BEARISH (price below SMAs)
- Long-term: BULLISH (price above SMA 200)
Support/Resistance Levels:
- Lower: $31.11 (Bollinger Band lower)
- Middle: $33.73 (SMA 20)
- Upper: $36.34 (Bollinger Band upper)
Momentum Signals: RSI: 68.79 (neutral), MACD signal line crossover above 0.25 (bullish), Bollinger Bands neutral
Volume Analysis:
- Volume SMA 20: 27316.75
- On-Balance Volume (OBV): 777767.39
- Volume Rate of Change: -67.63% (indicating low volume)
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines from the past two weeks, with no significant impact on the stock price.
Sentiment Assessment: Aggregate sentiment is NEUTRAL, with no clear bias towards bullish or bearish news.
Catalyst Identification: No specific catalysts identified in recent news; however, the options market suggests a potential $2.00 move by expiration.
Market Narrative: The recent neutral news headlines and low volatility regime suggest a stable environment, while the MACD signal implies potential for further gains.
Risk & Volatility Assessment
Risk Metrics:
- Beta: 0.71 (low risk relative to SPY)
- Alpha: 0.32
- Correlation: 0.43
- Stock Volatility: 0.21
Options Market Signals: IV Rank: 13.1% (Low), Current IV: 28.5%, Expected Move: $2.00 (28 DTE)
Market Context & Positioning
Sector Performance: IBBQ is trading within the Nasdaq Biotech sector, which has been relatively strong.
Institutional Activity: Volume patterns suggest institutional interest, but no clear directional bias.
Correlation Analysis: IBBQ is positively correlated with its peers and the broader market.
Relative Valuation: Positioned within a trading range; no clear relative value assessment can be made.
Key Levels & Action Items
Critical Price Levels:
- Lower: $31.11 (Bollinger Band lower)
- Middle: $33.73 (SMA 20)
- Upper: $36.34 (Bollinger Band upper)
Breakout/Breakdown Levels: No clear breakout or breakdown levels identified.
Time-Sensitive Catalysts: No specific earnings dates or product launches scheduled in the near term.
Risk Management: Stop-loss levels and position sizing considerations should be based on individual risk tolerance and market conditions.
Additional Notes
Data Interpretation: RSI >70 = neutral, MACD signal line crossover above 0.25 = bullish
News Impact Assessment: Recent news headlines have been generally neutral; no significant impact on the stock price.
Risk Assessment Criteria: High Risk: Not applicable due to low volatility and stable environment.
Conclusion IBBQ presents a mixed bag, with both bullish and bearish signals present. The stock's low volatility regime and neutral RSI reading indicate a stable environment, while the MACD signal suggests potential for further gains. Investors should consider the recent news headlines and options market signals in their analysis, and position themselves accordingly based on individual risk tolerance and market conditions.
Generated
News
All IBBQ news →
Zacks Investment ResearchT3·3d ago
Zacks Investment ResearchT3·4d ago
Zacks Investment ResearchT3·13d ago
Zacks Investment ResearchT3·14d ago
Zacks Investment ResearchT3·14d ago
Zacks Investment ResearchT3·14d ago
Zacks Investment ResearchT3·17d ago
Zacks Investment ResearchT3·17d ago
Zacks Investment ResearchT3·18d ago
Showing 1–10 of 50
Page 1 of 5
IBBQ Options Activity & IV Rank
IBBQ IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 28.5%
7-DTE IV: 34.1%
Expected Move: $2.67
7-DTE Move: $1.83
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 10
Put Volume: 3
P/C Volume: 0.3
BULLISH
Call OI: 13
Put OI: 2
P/C OI: 0.154
Total OI: 15
ATM Options Pricing
ATM Call: $1.12
ATM Put: $1.55
Call %: 3.1%
Put %: 4.2%
Chain Summary
Chain Volume: 13
Chain OI: 15
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)3.9LowNov 9
IV Rank (30 DTE)17.1LowNov 9
Straddle Price (30 DTE)$2.67Nov 9
Beta Analysis
Risk Metrics
Beta: 0.8115
Alpha: 26.11%
Correlation: 0.4781
R-Squared: 22.9%
Stock Volatility: 23.3%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
IBBQ Institutional Ownership (13F)
Filings for 2026-09-30
? 13F Guide
Diluted shares outstanding: 454,200,000 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
33.71K
SI % of Float
1.00%
Days to Cover
1.00
Short Vol Ratio
65.8%
Free Float
—
Float %
—
Short interest 2026-10-15 • Short volume 2026-11-09
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|